Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Abivax develops medicines that alter the body's natural immune system mechanisms.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
TCG Crossover has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
TCG Crossover's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Pharmaceutical. The firm invests across 13 different industry categories.
Among tracked funding rounds, Mirum Pharmaceuticals received $600.0M in a Post-IPO Debt round. TCG Crossover's total known invested capital is $9.9B.
TCG Crossover's average investment size is $187.1M across its portfolio of 76 companies.
Recent TCG Crossover portfolio additions include Vicebio, Allakos, RayzeBio, Korsana Biosciences, Versanis Bio. These companies were founded in 2020 or later.